Back

Cause of death and competing risk in patients with device-detected atrial fibrillation treated with apixaban or aspirin: Insights from the ARTESiA trial

13 April 2026 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Stroke in atrial fibrillation (2) Stroke in Atrial Fibrillation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor William McIntyre

Population Health Research Institute, Hamilton (Canada)

5 More presentations in this session

Presentation thumbnail
Impact of coronary artery calcium score on the risk prediction for ischemic stroke in patients with atrial fibrillation
Mr Y. Lee (Kwang Ju, KR)
Abstract Slides Video
Presentation thumbnail
Stroke risk stratification by coronary artery disease extent in patients with atrial fibrillation
Associate Professor K. Lee (Gwangju, KR)
Abstract Slides Video
Presentation thumbnail
An increase in stroke risk factors over time without arrhythmia recurrence does not require restarting anticoagulation in low-risk atrial fibrillation patients after successful ablation. (RESTART-AF)
Doctor A. Ballet (Antwerp, BE)
Abstract Slides Video
Presentation thumbnail
Incidence of left atrial thrombi in patients with atrial fibrillation and low thromboembolic risk: do we always need transesophageal echocardiography before rhythm control therapy?
Mr S. Koenig (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
Loneliness as an independent predictor of long-term stroke risk in atrial fibrillation patients: a UK biobank cohort analysis
Doctor B. Li (Xi'an, CN)
Abstract Slides

Access the full session

Session thumbnail
Stroke in atrial fibrillation (2)

The Event

Event poster

EHRA 2026

13 April 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Incidence and predictors of major bleeding among patients receiving apixaban or aspirin for subclinical atrial fibrillation: insights from the ARTESiA sub-analysis
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies
thumbnail
Congress Session
Late-Breaking Clinical Science: stroke prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources